Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | GABRP | O00591 | 1/20 | 0.37 |
| ▸ | GABRD | O14764 | 1/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.37 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.37 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.37 |
| ▸ | GABRE | P78334 | 1/20 | 0.37 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.37 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.37 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.37 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.37 |
| ▸ | IKBKB | O14920 | 1/20 | 0.36 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.35 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27917305 | 0.98 | KCNH2 (0.41) | KCNH2GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL699031 | 0.88 | KCNH2 (0.42) | KCNH2IKBKBICAM1SELERARB | |
| SCHEMBL9589800 | 0.81 | IKBKB (0.39) | KCNH2GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL2354951 | 0.78 | KCNH2 (0.47) | KCNH2KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL1512779 | 0.77 | GABRP (0.41) | KCNH2GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL18131021 | 0.77 | AURKA (0.32) | MAPKAPK2 | |
| SCHEMBL9755023 | 0.77 | KDM4E (0.39) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL6706595 | 0.77 | KCNH2 (0.43) | KCNH2MAPKAPK2KDM4EALDH1A1HPGD | |
| SCHEMBL28052421 | 0.76 | MAPKAPK2 (0.38) | KCNH2IKBKBMAPKAPK2 | |
| SCHEMBL3614621 | 0.76 | KDM4E (0.41) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1680116-A1 | COMBINATION TREATMENT OF OBESITY INVOLVING SELECTIVE CB1-ANTAGONISTS AND LIPASE INHIBITORS | Solvay Pharmaceuticals GmbH (DE) | 2006-07-19 | — | — | EP | claimed |
| EP-1663215-A1 | NOVEL MEDICAL USE OF SELECTIVE CB1- RECEPTOR ANTAGONISTS | Solvay Pharmaceuticals GmbH (DE) | 2006-06-07 | — | — | EP | claimed |
| US-20050101585-A1 | Use of selective CB1-antagonists in medical treatments | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-05-12 | — | — | US | claimed |
| WO-2005039579-A1 | COMBINATION TREATMENT OF OBESITY INVOLVING SELECTIVE CB1-ANTAGONISTS AND LIPASE INHIBITORS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-05-06 | — | — | WO | claimed |
| WO-2005020992-A1 | NOVEL MEDICAL USE OF SELECTIVE CB1-RECEPTOR ANTAGONISTS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-03-10 | — | — | WO | claimed |
| US-9592237-B2 | Use of CB1 antagonists and/or inverse agonists for the preparation of drugs that increase motor neuron excitability | FUNDACION DEL HOSPITAL NACIONAL DE PARAPLEJICOS PARA LA INVESTIGACION Y LA INTEGRACION (FUHNPAIIN) (ES) | 2017-03-14 | — | — | US | disclosed |
| US-20160106752-A1 | Use of CB1 Antagonists and/or Inverse Agonists for the Preparation of Drugs that Increase Motor Neuron Excitability | FUNDACION DEL HOSPITAL NACIONAL DE PARAPLEJICOS PARA LA INVESTIGACION Y LA INTEGRACION (FUHNPAIIN) (ES) | 2016-04-21 | — | — | US | disclosed |
| US-9238027-B2 | Use of CB1 antagonists and/or inverse agonists for the preparation of drugs that increase motor neuron excitability | FUNDACION DEL HOSPITAL NACIONAL DE PARAPLEJICOS PARA LA INVESTIGACION Y LA INTEGRACION (FUHNPAIIN) (ES) | 2016-01-19 | — | — | US | disclosed |
| US-20120149639-A1 | USE OF A DPP-IV INHIBITOR TO REDUCE HYPOGLYCEMIC EVENTS | BALKAN BOERK (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120142638-A1 | COMBINATION OF ORGANIC COMPOUNDS | WEBB RANDY LEE (US) | 2012-06-07 | — | — | US | disclosed |
| US-8143217-B2 | Use of DPP-IV inhibitor to reduce hypoglycemic events | NOVARTIS AG (CH) | 2012-03-27 | — | — | US | disclosed |
| US-20120015945-A1 | USE OF CB1 ANTAGONISTS AND/OR INVERSE AGONISTS FOR THE PREPARATION OF DRUGS THAT INCREASE MOTOR NEURON EXCITABILITY | FUNDACION DEL HOSPITAL NACIONAL DE PA | 2012-01-19 | — | — | US | disclosed |
| WO-2007035665-A1 | USE OF A DPP-IV INHIBITOR TO REDUCE HYPOGLYCEMIC EVENTS | NOVARTIS AG (CH) | 2007-03-29 | — | — | WO | disclosed |
| WO-2007006790-A2 | COMBINATION OF A DPP-IV INHIBITOR AND A CANNABINOID CB1 RECEPTOR ANTAGONIST | NOVARTIS AG (CH) | 2007-01-18 | — | — | WO | disclosed |
| CN-1845735-A | Novel medical use of selective cb1-receptor antagonists | SOLVAY PHARM GMBH (DE) | 2006-10-11 | — | — | CN | disclosed |
| EP-1680116-A1 | COMBINATION TREATMENT OF OBESITY INVOLVING SELECTIVE CB1-ANTAGONISTS AND LIPASE INHIBITORS | Solvay Pharmaceuticals GmbH (DE) | 2006-07-19 | — | — | EP | disclosed |
| EP-1663215-A1 | NOVEL MEDICAL USE OF SELECTIVE CB1- RECEPTOR ANTAGONISTS | Solvay Pharmaceuticals GmbH (DE) | 2006-06-07 | — | — | EP | disclosed |
| US-20050101585-A1 | Use of selective CB1-antagonists in medical treatments | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-05-12 | — | — | US | disclosed |
| WO-2005039579-A1 | COMBINATION TREATMENT OF OBESITY INVOLVING SELECTIVE CB1-ANTAGONISTS AND LIPASE INHIBITORS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-05-06 | — | — | WO | disclosed |
| WO-2005020992-A1 | NOVEL MEDICAL USE OF SELECTIVE CB1-RECEPTOR ANTAGONISTS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142638-A1 | COMBINATION OF ORGANIC COMPOUNDS | REN, ACE, CNR2 | KCNH2 1783/4885GABRP 468/4885GABRD 1345/4885 |
| US-20160106752-A1 | Use of CB1 Antagonists and/or Inverse Agonists for the Preparation of Drugs that Increase Motor Neuron Excitability | CNR1, CNR2, CHRNA9 | KCNH2 791/4885GABRP 35/4885GABRD 62/4885 |
| US-20120149639-A1 | USE OF A DPP-IV INHIBITOR TO REDUCE HYPOGLYCEMIC EVENTS | DPP4, DPP3, DPP7 | KCNH2 1126/4885GABRP 1040/4885GABRD 2574/4885 |
| US-20120015945-A1 | USE OF CB1 ANTAGONISTS AND/OR INVERSE AGONISTS FOR THE PREPARATION OF DRUGS THAT INCREASE MOTOR NEURON EXCITABILITY | CNR1, CNR2, CHRNA9 | KCNH2 791/4885GABRP 35/4885GABRD 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.